Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: lrb who wrote (2987)	11/25/1997 1:51:00 PM
From: Steve Fancy	Read Replies (2) \| Respond to of 6136

Just listened to a PW recording from Elise Wang from yesterday evening. Here are some notes from the call. - No fundamental reason for pull back - Her best guess, biotechs typically weak end of year, but typically come back in January - Continue to expect strong script data - Maintaining 12-month price target of 75 based on fiscal '98 $4.00 and change and industry multiple in the mid 40's. - Expect strong earnings report in early January...her estimate .12, if not better...expect stock to rebound strongly. - Expect positive data from Retrovirus meeting in February...twice daily dosage, combination therapy, resistance data. - Regarding one drug company...no question Viracept will be near term focus and likely for some time to come. - Don't feel Glaxo's drug will be available to end of '98 beginning of '99 and it's unclear how strong a competitor they will be - Don't see any competition as near term threat. - Rhinovirus...begin clinical studies soon, could be a very sizable market. - She mentioned Thymitaq later in '98, but I'm not sure as to what...will call and listen again later. - expecting strong rebound in 98. =================================================== Almost sounded like a might see futher downside, but don't panic kind of message. I've got mixed reactions at this point. sf